Crinetics Pharmaceuticals : Fundraising Choices in Life Sciences – When and Why
January 08, 2022 at 03:08 am IST
Share
LifeSci Partners Corporate Access Event
Panel: Fundraising Choices in Life Sciences - When and Why
Access to capital will always be the lifeblood of the biotech industry. Having a well-planned long-term equity financing strategy is arguably as important as an executive team's approach to deploy that capital. More than ever before, savvy investors look for management teams with the financial acumen to navigate the capital markets in addition to their traditional analysis of a company's pipeline fundamentals. Panelists will share their approach to the when and why of their fundraising choices.
Moderator:
Tom Rorke, LifeSci Advisors
Presenters:
Scott Struthers, CEO, Crinetics Pharmaceuticals, Inc.
Renee Aguiar-Lucande, CEO, Calliditas Therapeutics AB
Attachments
Original Link
Original Document
Permalink
Disclaimer
Crinetics Pharmaceuticals Inc. published this content on 07 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 January 2022 21:37:04 UTC.
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.